Isomorphic Labs Secures $2.1 Billion in Funding to Scale its AI Drug Design Engine

Isomorphic Labs, reimagining the drug discovery process with AI, led by Demis Hassabis and the team, has raised $2.1 Billion in Series B funding led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base.

The new capital will advance Isomorphic Labs’ AI drug design engine (IsoDDE), accelerating its therapeutic pipeline toward the clinic. It will also support global hiring across AI, engineering, drug design, and clinical teams to scale its AI-driven approach to tackling complex diseases.

This funding round further validates Isomorphic Labs’ progress in AI-driven drug design and marks a key milestone for the company. By combining proprietary AI, data, and a first-principles approach, Isomorphic Labs aims to redefine drug discovery with greater precision and speed than previously possible.

“The application of AI in healthcare represents a major opportunity,” said Ruth Porat, President and Chief Investment Officer at Alphabet and Google. “Isomorphic Labs has made strong progress in using AI to accelerate drug discovery, and this funding will help advance the platform and bring important treatments to market faster.”

“This funding round reflects strong confidence in our AI-first approach to drug design and development,” said Demis Hassabis. “With the foundation now proven, the focus shifts to scaling the technology and expanding the drug design engine to advance the mission of solving disease through AI.”

“This milestone reflects the strength of our AI drug design engine, which has already delivered key results across internal programs and identified viable candidates with exceptional speed,” said Max Jaderberg. “The platform is creating a repeatable approach to designing new medicines across a broad range of diseases.”

“We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all diseases,” said Joshua Kushner, Founder and CEO of Thrive Capital. "Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.”

“The team assembled by Isomorphic Labs is exceptional and continues to reinforce its leadership at the intersection of AI and drug discovery,” said Krishna Yeshwant. “There is strong confidence that the company’s approach can produce better-understood medicines earlier in the development process and expand what is possible in drug discovery.”

Technical Advancement and Strategic Impact

Isomorphic Labs has developed a unified AI drug design engine powered by proprietary models across multiple therapeutic areas and drug modalities. Recent IsoDDE advancements demonstrated strong predictive accuracy and scalable capabilities for real-world drug discovery.

The company also partners with major pharmaceutical leaders, including Novartis, Eli Lilly and Company, and Johnson & Johnson, validating its AI-first approach to medicine development.